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ABSTRACT 
Vascular anomalies are common in the upper extremity, but there continues to be a relative 
paucity of information about them in the hand and upper limb surgical literature. The wide 
spectrum of pathology and an inconsistent use of terminology make vascular anomalies 
susceptible to incorrect diagnosis and as a result to misdirected management. This article aims 
to provide an update on vascular anomalies relevant to the upper limb, focusing on significant 
advances in pathogenesis and genetics, classification systems, diagnosis, and treatment. 
Level of Evidence: V 
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ABSTRACT 4 
5 
Vascular anomalies are common in the upper extremity, but there continues to be a 6 
relative paucity of information about them in publications dealing with surgery in the 7 
hand and upper limb. The wide spectrum of pathology and an inconsistent use of 8 
terminology make vascular anomalies susceptible to incorrect diagnosis and as a 9 
result, to misdirected management. This article aims to provide an update on vascular 10 
anomalies relevant to the upper limb, focusing on significant advances in 11 
pathogenesis and genetics, classification systems, diagnosis, and treatment. 12 
13 
14 
3 
INTRODUCTION 15 
16 
Vascular anomalies account for 2-6% of all tumours in the upper extremity (Jacobs et 17 
al., 2010; McClinton, 1993; Mendel and Louis, 1997). However, there is a relative 18 
paucity of information about them in publications concerning surgery of the hand and 19 
upper limb. The wide spectrum of pathology ranging from minor "birthmarks" to 20 
complex life-threatening conditions (Wassef et al., 2015), as well as an inconsistent 21 
use of terminology make vascular anomalies susceptible to incorrect diagnosis and as 22 
a result, to misdirected management. This article aims to provide an update on 23 
vascular anomalies relevant to the upper limb by reviewing recent significant 24 
advances in pathogenesis and genetics, and to assess their influence on the evolution 25 
of classification systems, diagnosis, and treatment. 26 
27 
28 
VASCULAR DEVELOPMENT AND PATHOGENESIS OF VASCULAR 29 
ANOMALIES 30 
31 
The upper limbs of the developing human embryo form from around day 26 post-32 
fertilization and are fully formed by around day 56 (DeSesso, 2017; Vargesson and 33 
Hootnick, 2017). Vascular development is central to the normal formation and 34 
outgrowth of the limb, and occurs through the process of angiogenesis whereby 35 
existing vessels produce new vessels by the proliferation and migration of endothelial 36 
cells into new, previously avascular areas (usually induced through cellular hypoxia). 37 
Intersegmental arteries (that run in between the somites from the aorta) vascularize 38 
the limb bud by forming a capillary vascular plexus throughout the developing limb 39 
4 
bud and immediately after limb bud formation. (Vargesson, 2019 In Press ) Rapidly 40 
(within a day) one of the intersegmental vessels, the subclavian artery, becomes 41 
dominant and from then on solely supplies the outgrowing limb vascular plexus 42 
(Vargesson and Hootnick, 2017). As outgrowth of the limb bud continues, the 43 
vascular plexus starts to differentiate (with regression of some areas) in a proximal to 44 
distal manner, into distinctive arterial and venous patterns, which, owing to molecular 45 
differences, are prevented from fusing to maintain normal blood flow (Vargesson, 46 
2003). For example, the vascular plexus of the upper limb begins to differentiate so 47 
that the subclavian artery feeds into the axillary artery, which then feeds into the 48 
brachial artery (supplying parts of the humerus and upper arm). Subsequently, further 49 
differentiation of the vascular plexus occurs by splitting into the radial and ulnar 50 
arteries, which will ultimately lead into the arteries (e.g. the anterior interosseous) 51 
supplying the digital plate (DeSesso, 2017; Rodríguez-Niedenführ et al., 2001; 52 
Vargesson and Hootnick, 2017; Vargesson, 2019 In Press). This process, whereby the 53 
embryonic vascular plexuses develop into the adult vascular patterns, is also known as 54 
the vascular transition and occurs between week 5 and 7 (Levinsohn et al., 1991; 55 
Vargesson and Hootnick, 2017). The vascular transition accompanies and is 56 
intimately linked to the appearance of cartilage precursors of the bony elements, also 57 
in a proximal to distal fashion (Vargesson and Hootnick, 2017). For example, the 58 
humerus forms before the radius and ulna, which form before the digits – and as the 59 
elements form, they require vascularization to maintain outgrowth (Vargesson, 2003; 60 
Vargesson and Hootnick, 2017). Failure of the vascular transition or an inhibition into 61 
the correct vascular patterns causes vessels to be in the wrong position and can result 62 
in bony elements with reduced or no vascularization, which then results in malformed 63 
or missing bony elements (Levinsohn et al., 1991; Vargesson and Hootnick, 2017). 64 
 5 
Consequently, this mechanism has been proposed as an explanation for some 65 
congenital limb reduction syndromes (such as radial dysplasia) as well as for 66 
teratogen-induced limb differences (Levinsohn et al., 1991; Vargesson, 2015; 67 
Vargesson and Hootnick, 2017; Vargesson, 2019 In Press).  68 
 69 
In summary, the development of a functional and controlled vasculature is essential 70 
for normal limb development. Vascular failure, inhibition or disruption can result in 71 
congenital limb differences. Teratogens such as thalidomide can cause vessel failure 72 
and are linked with causation of limb differences through vascular loss (Therapontos 73 
et al., 2009; Vargesson, 2015). Other processes, such as thrombi from the maternal 74 
placenta as well as constriction bands have also been linked to the causation of  limb 75 
differences (Holmes et al., 2018).  76 
 77 
 78 
CLASSIFICATION 79 
 80 
Clinical classification 81 
The 1996 International Society for the Study of Vascular Anomalies (ISSVA) divided 82 
vascular lesions into proliferative vascular lesions or tumours (Enjolras, 1997) or 83 
vascular malformations. Vascular malformations were further subdivided on the basis 84 
of their predominant vessel type into capillary (CM), venous (VM), lymphatic (LM), 85 
arterial (AM), arterio-venous (AVM), or combined malformations (CVM). Additional 86 
disease entities have been identified and a more detailed understanding of the 87 
histopathology and genetics has led to the 2014 updated ISSVA classification (Table 88 
1). Vascular malformations can be further categorized based on their flow 89 
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characteristics, as determined by Doppler ultrasound, into low/no-flow (CM, LM, 90 
VM) and high-flow anomalies (AVM, arterio-venous Fistulas, AVF) (Mulliken et al., 91 
2000; Mulliken and Glowacki, 1982). 92 
 93 
Genetic classification 94 
More recently, modern genetic sequencing techniques have enabled the 95 
reclassification of vascular anomalies based on causative genetic mutations rather 96 
than on phenotypic subdivisions. Somatic mosaic mutations in the 97 
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) 98 
gene, which encodes the catalytic subunit of the enzyme Phosphatidylinositol 3-99 
kinase (PI3K), have been found in malformation/overgrowth syndromes (Figure 1). 100 
This led to the designation of the term “PIK3CA-Related Overgrowth Spectrum” of 101 
disorders (PROS), ranging from isolated anomalies to more complex segmental 102 
overgrowth disorders (Keppler-Noreuil et al., 2015). These recent genetic findings are 103 
likely to have significant impact on the understanding of vascular anomalies and their 104 
classification and medical treatments.  105 
 106 
 107 
CLINICAL PRESENTATIONS AND MANAGEMENT OF SPECIFIC 108 
VASCULAR TUMOURS 109 
 110 
Benign vascular tumours 111 
 112 
Infantile haemangioma (IH) is the most common tumour of infancy (Kilcline and 113 
Frieden, 2008) with an incidence within the limbs of around 15%. Most IHs appear 114 
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during the neonatal period within the first two weeks of life, but about one- third 115 
would already be present at birth, usually in the form of telangiectasia or a pink 116 
macular stain (Mulliken et al., 2000). Classically, IHs appear cherry red and lie in the 117 
papillary dermis (Figure 2). IHs are characterized by a typical pattern of initial rapid 118 
proliferative growth during the first 6 to 12 months, followed by a period of slow 119 
involution or regression over several years. In 50% of infants, involution is complete 120 
by five years , in 70% by seven years and the remainder by 10 years of age. After 121 
regression, 50% of affected children present with normal skin in the area of the 122 
former lesion, but larger lesions tend to leave an area of wrinkled skin overlying 123 
fibro-fatty tissue.  124 
 125 
As opposed to IHs, congenital haemangiomas (CH) are characterized by a distinct 126 
clinical course and histopathology. They form in utero, can be detected as early as in 127 
the second trimester of pregnancy, and are fully formed at birth (Boon et al., 1996; 128 
Bronshtein et al., 1992). CHs can be further divided into rapidly involuting (RICH), 129 
partly involuting (PICH), and non-involuting (NICH) types. Regression in RICH 130 
begins early, with full involution by 9 to 14 months.  NICHs persist as the child grows 131 
(Boon et al., 1996; Enjolras et al., 2001). Unlike IHs, their endothelial cells do not 132 
express Glut-1 (Wassef et al., 2015).  133 
 134 
Most haemangiomas on the upper limbs are small and regress following a predictable 135 
pattern without the need for intervention. Hence, they should be allowed to proliferate 136 
and involute under careful observation (Fevurly and Fishman, 2012). In cases of 137 
larger, more functionally incapacitating lesions, systemic propranolol might be 138 
considered as a first-line treatment (Holland et al., 2010). Topical Beta-blockers are 139 
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occasionally used but have so far shown only modest results (Pope and 140 
Chakkittakandiyil, 2010). 141 
 142 
Most commonly, decisions about surgery are delayed until complete involution has 143 
taken place. Early surgical intervention during the proliferative phase may be 144 
indicated in cases of recurrent infection, ulceration, or bleeding, especially when the 145 
haemangioma is well-localized. Early excision may also be considered in cases where 146 
removal is very likely to be required, even after involution, and the same optimal 147 
cosmetic result can be achieved (Fevurly and Fishman, 2012).  148 
 149 
Locally aggressive or borderline vascular tumours 150 
More invasive, benign, or locally aggressive and borderline vascular tumours of 151 
clinical significance are tufted angiomas (TA) and kaposiform 152 
hemangioendotheliomas (KHE). TA and KHE can be present at birth and are 153 
probably more of a spectrum of lesions than distinct entities although both lesions 154 
show distinct histopathological features. Clinically, they present with erythematous or 155 
brown plaques with surrounding ecchymosis and occasionally generalized petechiae 156 
(Figure 3).  157 
 158 
TA and KHE can be associated with profound thrombocytopenia (Kasabach-Merritt 159 
Phenomenon, KMP) (Enjolras et al., 1997), with a significant risk for intracranial, 160 
pleural-pulmonic, intraperitoneal, or gastro-intestinal haemorrhage with a mortality of 161 
up to 30% (Martinez-Perez et al., 1995). Sirolimus, an inhibitor of the PI3K/mTOR 162 
pathway, has now become a first-line treatment in KHE, and its use is rapidly 163 
 9 
expanding in the treatment of other vascular malformations and overgrowth 164 
syndromes (Enjolras et al., 2000; Gruman et al., 2005).  165 
 166 
Malignant vascular tumours 167 
In atypical presentations, malignant vascular tumours, although rare, must be kept in 168 
mind within the differential diagnosis. In unclear cases, a biopsy and 169 
histopathological diagnostics should be obtained. Management depends on the 170 
aggressiveness of the subtype and includes surgery and chemotherapy (Board, 2002).  171 
 172 
 173 
CLINICAL PRESENTATION AND MANAGEMENT OF SPECIFIC 174 
VASCULAR MALFORMATIONS 175 
 176 
Low flow vascular malformations 177 
Capillary malformations (CMs), often referred to as  “port wine stains” are composed 178 
of dilated capillaries and post-capillary venules that are located within the superficial 179 
dermis (Smoller and Rosen, 1986). Present at birth, they are the commonest vascular 180 
malformations, occurring in 0.3% of all new-borns (Jacobs et al., 2010). CMs 181 
generally persist lifelong and may demonstrate thickening and darkening due to vessel 182 
dilatation. They can be associated with overgrowth, or may be indicative of the 183 
presence of other vascular malformations (LM, VM) or syndromes (combined 184 
vascular malformations, vascular malformations associated with other anomalies) 185 
(Wassef et al., 2015). 186 
 187 
 10 
CMs on the upper extremity rarely require treatment other than for cosmetic reasons. 188 
The pulse-dye laser demonstrates good clinical response rates with a minimal 189 
complication risk. The optimal timing for laser treatment remains controversial, but 190 
early treatment appears beneficial (van der Horst et al., 1998). 191 
 192 
Lymphatic malformations (LMs) are composed of dilated channels or cysts and can 193 
be classified into microcystic (cysts <1cm), macrocystic (cysts >1cm), or mixed type 194 
lesions, depending on the diameter of the cysts (Figure 4). In the upper limb, LMs are 195 
generally of mixed type, but tend to be microcystic below the elbow. On inspection, 196 
the overlying skin of larger cysts can have a bluish appearance. Involved skin can also 197 
be thickened or puckered and may develop vesicles that have a propensity to weep, 198 
which increases the risk of infection. In the upper limbs, LMs are often associated 199 
with fibro-fatty tissues, and are most often confined to the skin and subcutis without 200 
penetration into the deep fascia or muscle. Occasionally, LMs are associated with 201 
skeletal overgrowth and distortion (Boyd et al., 1984), although they do not typically 202 
infiltrate bone or joints (Upton and Marler, 2005 ).  203 
 204 
Compression garments  can be effective as a first line measure for some symptomatic 205 
lesions (Jacobs et al., 2010); however, a lack of compressibility and the sheer size of 206 
some lesions can render compression ineffective. Additional problems associated with 207 
LMs include weeping, infections, and intralesional bleeding. Intralesional bleeding 208 
usually presents as rapid painful enlargement within the LM with associated 209 
ecchymosis. These episodes typically resolve with rest and analgesia. Pain and 210 
swelling may also occur as a result of bacterial or viral infection, which can be 211 
transmitted from a systemic infection into a LM. Early broadband spectrum antibiotic 212 
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treatment is indicated, and prolonged intravenous therapy may be required in order to 213 
adequately treat infection in recalcitrant cases.  214 
 215 
Sclerotherapy is a well-established treatment modality for LMs, especially those with 216 
a significant macrocystic component. Sclerotherapy is also used as an adjunct pre- 217 
and post-surgical debulking (Morgan et al., 2016).  There is a growing body of 218 
evidence supporting the efficacy of sirolimus (Morgan et al., 2016), which has been 219 
shown to be effective in trial cases of LMs and mixed lympho-venous malformations 220 
(Ricci, 2017; Trenor, 2016).  221 
 222 
 223 
Surgery for LMs can be complex, and careful planning is essential. Complete 224 
resection is often not possible, and recurrence rates of up to 30% have been reported 225 
(Morgan et al., 2016). The resection is often best  done in a staged manner (Upton and 226 
Marler, 2005) with the use of manoeuvres such as the administration of tranexamic 227 
acid, tourniquet control and diathermy assisted dissection to help minimize intra-228 
operative blood loss (Ghadimi et al., 2016). Pre-operative D-Dimer and fibrinogen 229 
levels can be useful predictors of the degree of vascularity in cases of mixed 230 
lymphovenous lesions. Incisions across joints and extensions into the axilla should be 231 
zigzagged to prevent joint contractures and allow for future growth. For each side of a 232 
digit, hand, or forearm, separate procedures should be used, and combined dorsal and 233 
palmar dissections should be avoided (Upton and Marler, 2005 ). Mid-lateral or 234 
medial incisions are less visible and therefore preferred over dorsal scars. Extensive 235 
poorly delineated lesions in the hand and forearm may be better suited to treatment 236 
with cautious sclerotherapy.  237 
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 238 
Venous malformations (VM) are mostly sporadic, generally occurring as solitary 239 
lesions. Clinically, they present as soft compressible masses that often have a bluish 240 
appearance when superficial (Figure 5). VMs are present at birth and can sometimes 241 
go unnoticed initially but will grow commensurately with the child. Expansion of 242 
venous lesions typically occurs during the adolescent growth spurt. Painful episodes 243 
of thrombosis within VMs are common due to a low rate of blood flow, and can lead 244 
to the formation of characteristic phleboliths (Wassef et al., 2015). VMs can be 245 
extensive, even involving the axilla and chest wall and extend across the deep fascia 246 
into muscles. Despite significant involvement, affected musculature of the upper limb 247 
may still function well. Recurrent haemarthrosis can be a debilitating problem in VMs 248 
surrounding joints (Upton et al., 1999).  249 
 250 
Glomuvenous malformations (GVMs) are distinct subsets of vascular malformation, 251 
characterised by the presence of a variable number of glomus cells (Boon et al., 252 
2004). They are typically found on the extremities and account for approximately 5% 253 
of all VMs. GVMs are characterised by their superficial location, characteristic pink 254 
to purple-blue colour, and so-called cobblestone appearance. Unlike VMs, GVMs are 255 
typically firm, and pain is aggravated by compression garments (Boon et al., 2004). 256 
They are usually well- localized and respond well to surgical excision. 257 
 258 
The basic surgical principles in VMs are very similar to those outlined for LMs. All 259 
possible measures to reduce bleeding must be considered.  Pre-operative sclerotherpy 260 
is useful in some cases to reduce the risk of bleeding from surgery (James et al., 2011; 261 
Morgan et al., 2016) and pre-operative optimization of clotting factors and treatment 262 
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with low molecular weight heparin to raise low fibrinogen levels can be beneficial in 263 
some cases with localised intravascular coagulation (LIC) (Dompmartin et al., 2008; 264 
Mazoyer et al., 2002; Zhuo et al., 2017). Complete resection is often not possible, as 265 
VMs tend to extend beyond the deep fascia and involve muscles more commonly than 266 
LMs. Furthermore, it must be remembered that muscle function is often remarkably 267 
good despite extensive infiltration. Therefore, resection of involved muscles must be 268 
considered very carefully (Upton and Marler, 2005 ). Post-operative custom-made 269 
compression garments are very useful for tamponading surgical fields and dressing 270 
around difficult anatomical contours, for example the axilla and limbs.  271 
 272 
Fibro-adipose vascular anomaly (FAVA) is a newly described fibro-fatty muscle-273 
infiltrating complex vascular malformation with clinical, radiological and 274 
histopathological features distinct from intramuscular VMs (Alomari et al., 2014; 275 
Fernandez-Pineda et al., 2014). FAVA patients typically present with unusually high 276 
levels of pain and sometimes joint contractures, and usually show a poor response to 277 
treatments such as sclerotherapy. In the upper limb, FAVAs typically affect the 278 
forearm musculature. 279 
 280 
FAVAs are characterized by a more solid, heterogeneous diffuse appearance on MRI 281 
and ultrasound imaging unlike classical VMs, which are more fluid (Johnson and 282 
Navarro, 2017). Surgery for FAVAs within the upper limb is difficult, as extensive 283 
muscle involvement and neurovascular entrapment are common (Figure 6). In these 284 
cases, compartment decompression, partial resection, neurolysis, and tendon 285 
lengthening can be very effective. In addition, image-guided percutaneous 286 
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cryoablation is emerging as a safe and effective treatment for symptomatic FAVA 287 
(Fernandez-Pineda et al., 2014; Shaikh et al., 2016).  288 
 289 
High flow vascular malformations 290 
 291 
 Owing to their locally aggressive nature, AVMs are the most formidable vascular 292 
malformation with potential to threaten limb and life.  They are high-flow lesions, 293 
consisting of disorganized arteries and veins that directly communicate by bypassing 294 
the high-resistance capillary bed (Fevurly and Fishman, 2012). With increased 295 
shunting, a phenomenon of blood flow ‘steal’ can occur, which leads to problems of 296 
distal ischaemia including pain, ulceration, and tissue necrosis (Upton and Marler, 297 
2005 ). The clinical progression of AVMs from quiescent to aggressive lesions with 298 
cardiac failure is reflected by the staging system  described by Schobinger (Kohout et 299 
al., 1998; Lowe et al., 2012) (Table 2). However, AVMs, particularly those affecting 300 
the upper limb, do not necessarily progress consecutively through each stage (Upton 301 
and Marler, 2005).  302 
 303 
Indications for operative treatment include uncontrollable progressive pain, digital 304 
ulceration, bleeding, compartment syndrome, cardiac failure or overall failure to 305 
thrive (Upton and Marler, 2005 ). Operative treatment is usually a combination of 306 
angiographic embolization and surgical resection. Pre-surgical embolization can 307 
improve outcomes and reduce morbidity (Morgan et al., 2016).  308 
 309 
Combined vascular malformations 310 
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Combined vascular malformations (CVMs) contain at least two vascular 311 
malformations in one lesion; they can be simple malformations, malformations of 312 
major named vessels or a combination of both types. Multiple combinations exist;  313 
these lesions are often associated with skeletal and soft tissue overgrowth and 314 
abnormalities of the viscera and in rare cases undergrowth (Boyd et al., 1984). The 315 
principles of CVM management are similar to those outlined above for simple 316 
vascular malformations.  317 
 318 
Vascular malformations associated with other anomalies 319 
Klippel-Trenaunay-syndrome (KTS) represents a triad of capillary malformation, 320 
lympho-venous malformation and limb overgrowth. More recently, it has been shown 321 
that what was classically described as KTS is actually part of a spectrum of conditions 322 
that result from PIK3CA-related somatic mosaic mutations (Figure 1). KTS 323 
characteristically affects one lower extremity (88%) (Figure 7A), but bilateral cases 324 
and involvement of an upper extremity (29%) (Figure 7B), and extension into the 325 
trunk (23%) are not uncommon (Jacob et al., 1998; Lobo-Mueller et al., 2009).  326 
 327 
CLOVES is an acronym (Congenital, Lipomatous, Overgrowth, Vascular 328 
malformations, Epidermal naevi and Spinal/Skeletal anomalies and/or Scoliosis, 329 
Seizures) for a syndrome with underlying somatic activating mutations in PIK3CA 330 
(Alomari, 2009; Kurek et al., 2012; Sapp et al., 2007). The clinical signs are usually 331 
present at birth and may be identified by prenatal imaging (Fevurly and Fishman, 332 
2012). CLOVES is characterized by limb asymmetry with involvement of the upper 333 
limb in 50% of cases. The typical lipomatous masses on the trunk and/or limbs are 334 
accompanied by overlying CM and other associated low flow lesions (VM, LM) and 335 
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high-flow (AVM) vascular malformations. Other manifestations include epidermal 336 
nevi, bony anomalies including scoliosis, acral anomalies such as wide or triangular 337 
feet, syndactyly or macrodactyly and a widened gap between the first and the second 338 
toes (sandal gap).  339 
 340 
Proteus syndrome (PS) is a rare condition that typically presents with segmental 341 
overgrowth, vascular anomalies including CM, VM, and LM, epidermal nevi, 342 
hyperplasia of multiple tissues, and a propensity to develop tumours (Figure 8). A 343 
mosaic somatic mutation of the AKT1 gene has been found in more than 90% of 344 
patients with PS (Johnson and Navarro, 2017). The striking phenotypic resemblance 345 
of Proteus to “PIK3CA-Related Overgrowth Spectrum” of disorders (PROS) might be 346 
because AKT1 is a downstream of PIK3CA and therefore activates similar 347 
downstream elements. In contrast to PROS disorders, the lesions in PS are not present 348 
at birth, but are characterized by progressive disproportionate overgrowth and may 349 
present with pathognomonic connective tissue naevi (Biesecker et al., 1999).  350 
 351 
Parkes Weber syndrome (PWS) is distinguished from KTS by the presence of a high-352 
flow arterio-venous malformation, in addition to a capillary one (CAVM) and limb 353 
hypertrophy (Weber, 1908; Weber, 1918; Young, 1988). PWS is caused by mutations 354 
in RASA1, an inhibitor of cellular growth, proliferation and differentiation. The 355 
lesions involve skin, muscle, and bone, and the overgrowth becomes increasingly 356 
prominent with growth, especially at puberty, after trauma to the limb, or during 357 
pregnancy. The lesions are present at birth and marked by a pink, warm, macular CM 358 
overlying the asymmetrically enlarged limb, often with an AVM heralded by an 359 
audible bruit and palpable thrill. Although PWS is more common in the lower 360 
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extremity, the upper limb is affected in about 23% of cases (Upton and Marler, 2005). 361 
The high-flow lesions can lead to symptoms as severe as heart failure. 362 
 363 
Maffucci syndrome is a rare congenital condition that is characterized by 364 
simultaneous occurrence of multiple enchondromas and spindle cell haemangiomas 365 
that most commonly affect both hands resulting in deformities. Malignant 366 
transformation has been described, and over 30% of the enchondromas progress to 367 
chondrosarcomas. Patients with Maffucci syndrome also have an increased risk for 368 
other secondary malignancies, including gliomas. In 77% of these patients, somatic 369 
mutations in Isocitrate dehydrogenase (IDH) have been identified. Similar to Ollier’s 370 
disease (which does not include haemangiomas and is typically unilateral), 371 
monitoring with periodic physical and radiographic examination is required  because 372 
of the risk of malignant transformation (Fatti and Mosher, 1986). 373 
 374 
 375 
SUMMARY 376 
The management of vascular anomalies remains demanding, but advances in 377 
interventional radiology, surgery and newer medical treatments have been promising. 378 
Systemic therapies, which could inhibit overgrowth and reduce vascular 379 
malformations by altering the PI3K-AKT-mTOR pathway in patients with PIK3CA 380 
mutations (Lackner et al., 2015) have the potential to revolutionize the management 381 
of vascular malformations (Keppler-Noreuil et al., 2015). Sirolimus, an inhibitor of 382 
the PI3K/mTOR pathway, is now being broadly applied in trials to a wide range of 383 
pathologies across the spectrum of vascular anomalies. Furthermore, newer 384 
generations of similar drugs are under development, including everolimus (Ricci, 385 
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2017; Trenor, 2016). Overall, these advances will aid the multi-disciplinary 386 
management of this wide ranging and often complex spectrum of conditions. 387 
 388 
  389 
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Figure legends 615 
616 
Figure 1: PI3K-AKT Pathway and associated clinical overgrowth disorders 617 
(reproduced with permission from Keppler-Noreuil et al., 2014 (John Wiley and 618 
Sons)) 619 
620 
Figure 2: Infantile haemangioma 621 
A patient with an infantile haemangioma on forearm and wrist. Note areas of 622 
involution with settling of discolouration.  623 
624 
Figure 3: Kaposiform haemangioendothelioma (KHE) 625 
A patient with KHE affecting the right arm. This patient was successfully treated with 626 
sirolimus.  627 
628 
Figure 4: Lymphatic malformation 629 
A patient with an extensive lymphatic malformation affecting the length of the arm. 630 
Note the lesion predominantly affects the tissues above the deep fascia.  631 
632 
29 
Figure 5: Venous malformation 633 
A patient with a venous malformation affecting the thumb pulp. Note the lesion 634 
engulfs the neurovascular structures within the thumb and involves the entire pulp 635 
tissue.  636 
637 
Figure 6: Fibro-adipose vascular anomaly (FAVA) of the forearm. 638 
A patient who had extensive involvement of the flexor compartment of the forearm. 639 
Intra-operative pictures of a forearm compartment decompression and neurolysis of 640 
the median and ulna nerves. Note a central area of focal thrombosis has been excised 641 
from the flexor digitorum superficialis (FDS) musculature.  642 
643 
Figure 7: Patient with PIK3CA overgrowth spectrum 644 
(A) Involvement of the leg with a low flow malformation, limb overgrowth, and a645 
capillary malformation. 646 
(B) Same patient with macrodactylous overgrowth of the ring finger.647 
648 
Figure 8: Proteus syndrome 649 
Hand manifestations of a patient with Proteus syndrome. 650 
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Table 1. Vascular anomalies based on the International Society for the Study of Vascular Anomalies (ISSVA) classification, 2014. Modified from 
(Morgan et al., 2016). 
 
Vascular tumours Vascular malformations 
Simple Combined 
Benign vascular tumours: Capillary malformations (CM) Defined as two or more vascular malformations 
identified in one lesion. Can be composed of any 
combination CM, LM, VM, AVM. 
  Infantile haemangioma (IH) 
  Congenital haemangioma Lymphatic malformations (LM) 
     Rapidly involuting (RICH) 
     Non-involuting (NICH) Venous malformations (VM) 
     Partially involuting (PICH) 
  Tufted Angioma (TA) Arteriovenous malformations (AVM) 
  Spindle-cell haemangioma 
  Epitheloid haemangioma Arteriovenous fistulas (AVF) 
  Pyogenic granuloma (PG) 
  Others Of named major vessels Associated with other anomalies 
Table 1
Locally aggressive vascular tumours: “Channel type” or “truncal” malformations Klippel-Trenaunay-syndrome (KTS) 
  Kaposiform Haemangioendothelioma (KHE) Parkes Weber syndrome (PWS) 
  Retiform haemangioendothelioma Servelle-Martorell syndrome 
  Composite haemangioendothelioma Sturge-Weber syndrome 
    Dabska tumour Limb CM + limb hypertrophy 
  Kaposi sacroma Maffucci syndrome 
  others Macrocephaly-CM 
Malignant vascular tumours Microcephaly-CM 
  Angiosarcoma of the soft tissue CLOVES syndrome 
  Epitheloid haemangioendothelioma Proteus syndrome (PS) 
  Others Banayan-Riley-Ruvalcaba syndrome 
 
 
Table 2. Schobinger clinical staging system for AVM. From (Kohout et al., 1998). 
 
Stage  Description 
I Quiescent  
 
Pink-bluish stain, increased warmth, arteriovenous 
shunting detectable with continuous Doppler scanning or 
20 MHz colour Doppler scanning  
II Expansion Stage I +  
Enlargement, pulsations, thrill and bruits and tortuous/ 
tense veins 
III Destruction Stage II + either  
dystrophic skin changes, ulceration, bleeding, persistent 
pain 
or  
tissue necrosis 
IV Decompensation Stage III + 
Cardiac failure 
 
Table 2
